Core Points - Leviathan Gold Ltd. announced the completion of a private placement financing by Cura Exploration Botswana Corp. for gross proceeds of $3,500,000, which satisfies the financing condition for the proposed acquisition of Cura [1] - An extension agreement has been entered into between Leviathan and Cura, allowing until September 30, 2025, to finalize a definitive agreement for the proposed transaction [2] - The trading of Leviathan's common shares on the TSX Venture Exchange was halted on June 16, 2025, pending review due to the proposed transaction being classified as a "Fundamental Acquisition" [3] Financing and Acquisition Details - The private placement financing by Cura raised $3,500,000, which is a critical step for Leviathan's acquisition plans [1] - The extension agreement provides additional time for both parties to negotiate and finalize the terms of the acquisition [2] - The halt in trading will be lifted once the TSXV reviews the necessary technical reports and documentation related to the acquisition [3] Regulatory Compliance - The proposed transaction is subject to TSX Venture Exchange Policy 5.3, which governs acquisitions and dispositions of non-cash assets [3] - Leviathan and Cura are currently preparing the required documentation, including technical reports and financial statements, to comply with TSXV regulations [3] Company Overview - Leviathan Gold Ltd. is a Canadian-based mineral exploration company listed on the TSXV and in Germany [4]

SUNRISE, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (Nasdaq: AENT), a leading distributor and fulfillment partner of entertainment and pop culture collectibles, is thrilled to announce the release of three new Collector-Edition Handmade by Robots™ vinyl figures featuring the iconic Leatherface from the legendary horror film, The Texas Chain Saw Massacre. This release coincides with Texas Chain Saw Day, a nationwide theatrical celebration honoring the film’s enduring l ...

LIVERMORE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ: ADN) an innovation-driven leader in the fuel cell and hydrogen technology sector, is supplying its proprietary membrane electrode assembly technology to Stralis Aircraft, based in Australia, for their hydrogen electric Beechcraft Bonanza aircraft. Emory De Castro, the Chief Technology Officer of the Company stated, “we continue to work closely with the team at Stralis on their next generation high temperature (H ...

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2 ...

Core Viewpoint - NeuroOne Medical Technologies Corporation has received FDA clearance for its OneRF Trigeminal Nerve Ablation System, which offers a minimally invasive alternative for treating trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people annually in the U.S. [1][2] Group 1: Product and Technology - The OneRF Trigeminal Nerve Ablation System utilizes a proprietary RF generator platform to create radiofrequency lesions for pain treatment and functional neurosurgical procedures [1][2] - This system features a unique multi-contact RF probe that allows for precise localization and tailored ablation of nerve tissue, enhancing safety and accuracy during procedures [3] - The technology aims to reduce procedural time, improve patient comfort, and enhance overall patient safety [3] Group 2: Market Potential and Strategy - The company plans a limited commercial launch of the OneRF system in the fourth quarter of 2025, with expectations to generate revenues from trigeminal nerve ablation by late 2025 [1][4] - NeuroOne's technology platform has potential applications across various neurological disorders and pain management functions, including lower back pain [4] - Current users of the OneRF brain ablation system may also adopt the nerve ablation procedures, justifying further investment in the technology [4] Group 3: Company Overview - NeuroOne Medical Technologies Corporation focuses on developing minimally invasive solutions for various neurological disorders, including epilepsy and chronic pain [5] - The company is exploring additional therapeutic applications, such as treatments for depression, mood disorders, and high blood pressure [5]

ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immedi ...

HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by ...

Climate change Industry leaders in environmental infrastructure delivery HOUSTON, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) and Abundia Global Impact Group (AGIG), announced the appointment of Nexus PMG (Nexus) as its Engineering and Service provider to support the development of AGIG’s Plastics Recycling Facility and Innovation Hub on the site acquired in July 2025 at the Cedar Port Industrial Park in Baytown, TX. Nexus’s expertise i ...

August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first two patients by the Pan American Center for Onc ...

Core Viewpoint - Energi Holdings Limited will acquire a 51% stake in Tembo e-LV B.V. from VivoPower International PLC, enabling Tembo to proceed with its SPAC merger at an equity valuation of $838 million [1][2]. Group 1: Investment Details - The total enterprise valuation for 100% of Tembo is set at $200 million, with the equity purchase price for the 51% stake adjusted for Tembo's net debt and customary adjustments at closing [2]. - The investment is contingent upon the completion of Tembo's business combination agreement with Cactus Acquisition Corp 1 Limited and customary closing conditions [2]. Group 2: Corporate Structure and Strategy - VivoPower has initiated the recruitment of a dedicated board of directors for Tembo in preparation for its public listing [3]. - VivoPower is undergoing a strategic transformation to focus on XRP and digital assets, aiming to support decentralized finance infrastructure and blockchain applications [4]. Group 3: Company and Subsidiary Overview - VivoPower operates globally with a focus on sustainable energy solutions and has two business units: Tembo and Caret Digital [5]. - Tembo specializes in battery-electric and off-road vehicle solutions for various industrial sectors, including mining and agriculture, providing electrification solutions for utility vehicle fleet owners [6].